Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, have filed a Schedule 13G with the United States Securities and Exchange Commission on April 5, 2024, indicating a shared voting and dispositive power over 114,775 shares of Avalo Therapeutics, Inc. This represents 9.99% of the company's class of common stock. The filing, which is required due to the acquisition of shares that meet the threshold for reporting, states that the shares include 1,940.68125 Series C Non-Voting preferred stock and 1,164,408 warrants, both subject to a beneficial ownership limitation of 9.99%. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics, Inc. and were not held in connection with any transaction having that purpose or effect. The principal business offices of the reporting persons are located in Delaware, the Cayman Islands, and the United States, respectively.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, have filed a Schedule 13G with the United States Securities and Exchange Commission on April 5, 2024, indicating a shared voting and dispositive power over 114,775 shares of Avalo Therapeutics, Inc. This represents 9.99% of the company's class of common stock. The filing, which is required due to the acquisition of shares that meet the threshold for reporting, states that the shares include 1,940.68125 Series C Non-Voting preferred stock and 1,164,408 warrants, both subject to a beneficial ownership limitation of 9.99%. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics, Inc. and were not held in connection with any transaction having that purpose or effect. The principal business offices of the reporting persons are located in Delaware, the Cayman Islands, and the United States, respectively.